Michael Drake V
Known title: DirectorCIK: 0001938942
Associated companies
Transaction History
| AMGN | ▲ Buy | Grant | 64 | $0 | 8/7/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 665 | $0 | 5/19/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 80 | $0 | 5/5/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 219 | $0 | 11/7/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 121 | $0 | 8/8/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 809 | $0 | 5/23/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 129 | $0 | 5/6/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 221 | $0 | 11/4/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 109 | $0 | 8/9/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 719 | $0 | 5/31/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 117 | $0 | 5/7/2024 | View on chart |
| AMGN | ▲ Buy | Grant | 241 | $0 | 11/3/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 125 | $0 | 8/8/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 939 | $0 | 5/19/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 138 | $0 | 5/2/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 171 | $0 | 11/8/2022 | View on chart |
| AMGN | ▲ Buy | Grant | 634 | $0 | 8/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Amgen Outperforms Market Amid Dow Jones Rotation
Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.
Amgen Outperforms Market Amid Dow Jones Rotation. Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.